Visit for the latest Coronavirus Disease (COVID-19) updates.

You are here

IID-1.7 Data Details

Expand All

IID-1.7 Reduce cases of pertussis among adolescents aged 11 to 18 years

About the Data

Description of the data source, numerator, denominator, survey questions, and other relevant details about the national estimate.

Data Source: 
National Notifiable Diseases Surveillance System
Changed Since the Healthy People 2020 Launch: 
Baseline (Year): 
3,995 (2000–04)
Target-Setting Method: 
Projection/trend analysis
Target-Setting Method Justification: 
The duration of protection afforded by the Tdap vaccine is unclear. As adolescent vaccination coverage of Tdap increases, a reduction of disease in adolescents will occur. Results from observational vaccine effectiveness evaluation have shown Tdap vaccine to be approximately 80 percent effective. Within the adolescent population(11 to 18 years of age), Tdap coverage will reach 70 percent. Therefore, with 70 percent Tdap coverage and approximately 80 percent effectiveness, reported pertussis incidence may reasonably be reduced by approximately 50 percent.

Number of confirmed and probable cases of pertussis (including cases identified in outbreak settings) among persons aged 11 to 18 years

Comparable Healthy People 2010 Objective: 
Not applicable
Data Collection Frequency: 
Methodology Notes: 

    Estimates represent the mean number of Confirmed, Probable, and Unknown cases (aged 11-18 years) of pertussis reported to NNDSS during the relevant data years. Only adolescent cases with known sex and race/ethnicity are included for sex and race/ethnicity estimates.

    A case definition for confirmed and probable cases of pertussis (including cases identified in outbreak settings) is available from CDC. Estimates are a five-year moving average of confirmed and probable cases of pertussis reported to the National Notifiable Disease Surveillance System (NNDSS).


Additional resources about the objective

  1. Centers for Disease Control and Prevention (CDC). Case definitions for infectious conditions under public health surveillance. Morbidity and Mortality Weekly Report 46 (RR-10), 1997. (See reference for updated case definitions.)